<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11178">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00595075</url>
  </required_header>
  <id_info>
    <org_study_id>Takeda - 103113</org_study_id>
    <nct_id>NCT00595075</nct_id>
  </id_info>
  <brief_title>Ramelteon for a Nap Prior to a Night Shift</brief_title>
  <official_title>Effects of Ramelteon on Sleep and Neurobehavioral Performance in a Simulated Night Shift Preceded by a Sleep Opportunity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Night shift-workers are often advised to take a prophylactic nap prior to starting the shift
      in order to improve alertness and performance. However, individuals often report difficulty
      initiating and maintaining sleep at that time of the day secondary to the alerting influence
      of the near-24 hour circadian rhythm (biological clock). A sleep-promoting medication may
      improve the quality of an evening nap and subsequent alertness and performance during a
      night shift. We will use Ramelteon, a melatonin agonist that is FDA approved for insomnia,
      in order to test the following hypotheses:

        1. ramelteon, compared with placebo, will significantly increase sleep efficiency during a
           2-hour nap;

        2. sleep inertia, as assessed by neurobehavioral tests and subjective and objective
           sleepiness assessments will not be significantly increased after ramelteon treatment
           compared with placebo treatment; and

        3. neurobehavioral performance, subjective and objective sleepiness, and subjective mood
           during a simulated 8-hour night shift will be significantly improved when ramelteon is
           given prior to a prophylactic nap compared to a prophylactic nap with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>total sleep time/time in bed * 100% (higher values indicate better outcome)</description>
  </primary_outcome>
  <other_outcome>
    <measure>Post-nap Assessment - Visual Analog Scale</measure>
    <time_frame>71 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>numerical scale of increasing alertness from 0-100 (higher values are better outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Post Nap Assessment - Karolinska Sleepiness Scale</measure>
    <time_frame>71 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>numerical scale of increasing sleepiness from 1-9 (higher values indicate worse outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Post Nap Assessment - Digit Symbol Substitution Test (Correct Answers)</measure>
    <time_frame>71 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>A cognitive throughput task consisting of matching symbols to numerical keys; higher numbers indicate a better score</description>
  </other_outcome>
  <other_outcome>
    <measure>Post Nap Assessment - Karolinska Drowsiness Test</measure>
    <time_frame>71 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>EEG spectral analysis of 5.5-9.0 Hz frequency activity (theta low-frequency alpha), with higher activity indicating increased drowsiness and worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Psychomotor Vigilance Task - Median Reaction Time</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual-motor reaction time in which participants hit a button on a response box as fast as possible in response to a visual target (lower values indicate better outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Psychomotor Vigilance Task - Number of Lapses</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of trials per test battery with a reaction time &gt;0.5 seconds (higher values indicate worse outcome)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramelteon 8 mg will be given once prior to a 2-hour nap</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be given once prior to a 2-hour nap</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon</intervention_name>
    <description>Ramelteon 8 mg tablet by mouth x 1 dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rozerem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo identical in appearance to active experimental drug x 1 dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18-35 years;

          -  Non-smoking for at least 6 months;

          -  Healthy (no medical, psychiatric or sleep disorders);

          -  No clinically significant deviations from normal in medical history, vital signs,
             physical examination, blood chemistry and hematology, and ECG;

          -  Women of childbearing potential must agree to use an acceptable method of birth
             control, and must have a negative serum pregnancy test;

          -  Body mass index of &gt; 18 or &lt; 30 kg/mâˆ§2;

          -  No drugs or medication likely to affect sleep or alertness, as determined by the
             investigators;

          -  Habitual caffeine consumption &lt; 300 mg per day on average;

          -  Habitual alcohol consumption &lt; 10 alcoholic units per week on average.

        Exclusion Criteria:

          -  History of alcohol or substance abuse;

          -  Positive result on drugs of abuse screening;

          -  Current or past history of sleep disorders, including but not limited to obstructive
             sleep apnea, or any significant sleep complaint;

          -  Psychiatric disorder, including a history of depression or dysthymia (characterized
             by depressed mood on the majority of days for at least two years);

          -  Recent acute or chronic medical disorder, including but not limited to hepatic
             impairment and severe chronic obstructive pulmonary disease;

          -  History of intolerance or hypersensitivity to melatonin or melatonin agonists;

          -  Pregnancy or lactation;

          -  Shift work;

          -  Transmeridian travel (2 or more time zones) in past 2 months;

          -  Any other scientific or medical reason, as determined by the PI, such as
             non-compliance with protocol or intolerance to inpatient study conditions.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shantha Rajaratnam, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hosptial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth B Klerman, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://sleep.med.harvard.edu/research/recruitment</url>
    <description>Harvard Division of Sleep Medicine website</description>
  </link>
  <results_reference>
    <citation>Cohen DA, Wang W, Klerman EB, Rajaratnam SM. Ramelteon prior to a short evening nap impairs neurobehavioral performance for up to 12 hours after awakening. J Clin Sleep Med. 2010 Dec 15;6(6):565-71.</citation>
    <PMID>21206545</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 24, 2012</lastchanged_date>
  <firstreceived_date>January 7, 2008</firstreceived_date>
  <firstreceived_results_date>July 22, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Elizabeth B. Klerman</investigator_full_name>
    <investigator_title>Associate Professor, Associate Physician</investigator_title>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>performance</keyword>
  <keyword>night shift</keyword>
  <keyword>Ramelteon</keyword>
  <keyword>Healthy Individuals</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy volunteers were recruited</recruitment_details>
      <pre_assignment_details>Participants received 1 dose of ramelteon or placebo during the first inpatient visit and then returned approximately four weeks later for the other condition, counterbalanced for order</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ramelteon in First Crossover Period</title>
          <description>Ramelteon 8 mg will be given prior to a 2-hour nap</description>
        </group>
        <group group_id="P2">
          <title>Placebo in First Crossover Period</title>
          <description>Placebo will be given prior to a 2-hour nap</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ramelteon in First Crossover Period</title>
          <description>Ramelteon 8 mg will be given prior to a 2-hour nap</description>
        </group>
        <group group_id="B2">
          <title>Placebo in First Crossover Period</title>
          <description>Placebo will be given prior to a 2-hour nap</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="22.7" spread="4.1"/>
                <measurement group_id="B2" value="26.8" spread="3.2"/>
                <measurement group_id="B3" value="24.5" spread="4.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sleep Efficiency</title>
        <description>total sleep time/time in bed * 100% (higher values indicate better outcome)</description>
        <time_frame>2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants that completed both crossover periods</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Ramelteon 8 mg will be given prior to a 2-hour nap</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given prior to a 2-hour nap</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sleep Efficiency</title>
            <description>total sleep time/time in bed * 100% (higher values indicate better outcome)</description>
            <units>percent</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="89.1" spread="9.8"/>
                  <measurement group_id="O2" value="83.3" spread="14.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post-nap Assessment - Visual Analog Scale</title>
        <description>numerical scale of increasing alertness from 0-100 (higher values are better outcome)</description>
        <time_frame>71 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants that completed both crossover periods</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Ramelteon 8 mg will be given prior to a 2-hour nap</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given prior to a 2-hour nap</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Post-nap Assessment - Visual Analog Scale</title>
            <description>numerical scale of increasing alertness from 0-100 (higher values are better outcome)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61.1" spread="18.6"/>
                  <measurement group_id="O2" value="67.1" spread="22.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post Nap Assessment - Karolinska Sleepiness Scale</title>
        <description>numerical scale of increasing sleepiness from 1-9 (higher values indicate worse outcome)</description>
        <time_frame>71 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants that completed both crossover periods</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Ramelteon 8 mg will be given prior to a 2-hour nap</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given prior to a 2-hour nap</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Post Nap Assessment - Karolinska Sleepiness Scale</title>
            <description>numerical scale of increasing sleepiness from 1-9 (higher values indicate worse outcome)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.4" spread="1.6"/>
                  <measurement group_id="O2" value="4.8" spread="1.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post Nap Assessment - Digit Symbol Substitution Test (Correct Answers)</title>
        <description>A cognitive throughput task consisting of matching symbols to numerical keys; higher numbers indicate a better score</description>
        <time_frame>71 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants that completed both crossover periods</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Ramelteon 8 mg will be given prior to a 2-hour nap</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given prior to a 2-hour nap</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Post Nap Assessment - Digit Symbol Substitution Test (Correct Answers)</title>
            <description>A cognitive throughput task consisting of matching symbols to numerical keys; higher numbers indicate a better score</description>
            <units>correct answers</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50.4" spread="9.3"/>
                  <measurement group_id="O2" value="53.3" spread="9.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post Nap Assessment - Karolinska Drowsiness Test</title>
        <description>EEG spectral analysis of 5.5-9.0 Hz frequency activity (theta low-frequency alpha), with higher activity indicating increased drowsiness and worse outcome</description>
        <time_frame>71 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants completing both crossover periods</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Ramelteon 8 mg will be given prior to a 2-hour nap</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given prior to a 2-hour nap</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Post Nap Assessment - Karolinska Drowsiness Test</title>
            <description>EEG spectral analysis of 5.5-9.0 Hz frequency activity (theta low-frequency alpha), with higher activity indicating increased drowsiness and worse outcome</description>
            <units>microvolts^2/Hz</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.9" spread="4.5"/>
                  <measurement group_id="O2" value="4.0" spread="5.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Psychomotor Vigilance Task - Median Reaction Time</title>
        <description>Visual-motor reaction time in which participants hit a button on a response box as fast as possible in response to a visual target (lower values indicate better outcome)</description>
        <time_frame>8 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants completing both crossover periods</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Ramelteon 8 mg will be given prior to a 2-hour nap</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given prior to a 2-hour nap</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Psychomotor Vigilance Task - Median Reaction Time</title>
            <description>Visual-motor reaction time in which participants hit a button on a response box as fast as possible in response to a visual target (lower values indicate better outcome)</description>
            <units>seconds</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.662" spread="0.16"/>
                  <measurement group_id="O2" value="0.362" spread="0.25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Psychomotor Vigilance Task - Number of Lapses</title>
        <description>Number of trials per test battery with a reaction time &gt;0.5 seconds (higher values indicate worse outcome)</description>
        <time_frame>8 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants completing both crossover periods</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Ramelteon 8 mg will be given prior to a 2-hour nap</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given prior to a 2-hour nap</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Psychomotor Vigilance Task - Number of Lapses</title>
            <description>Number of trials per test battery with a reaction time &gt;0.5 seconds (higher values indicate worse outcome)</description>
            <units>lapses</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15.5" spread="16.3"/>
                  <measurement group_id="O2" value="13.2" spread="16.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During each 28-hr inpatient study admission</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ramelteon</title>
          <description>Ramelteon 8 mg will be given prior to a 2-hour nap</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo will be given prior to a 2-hour nap</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Circadian phase was not measured.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Daniel Cohen</name_or_title>
      <organization>Sentara Neurology Specialists</organization>
      <phone>757-388-6323</phone>
      <email>dacohen@sentara.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
